Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022
05/02/2022 - 04:30 PM
Marlborough, Mass. , May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it will present new preclinical data on PH-894 for use in adoptive cell therapy (ACT) at the American Society for Gene and Cell Therapy (ASGCT) 25th Annual Meeting, which is being held May 16-19, 2022 in-person in Washington, D.C. and virtually.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Poster Details are as follows:
Title:
Self-Delivering RNAi Targeting BRD4 (PH-894) Improves the
Author:
Benjamin Cuiffo, et al.
Abstract Number:
222
Session:
Oligonucleotide Therapeutics I
Session Date and Time:
Monday, May 16, 2022 5:30 PM - 6:30 PM EDT
Location:
Walter E. Washington Convention Center, Hall D
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. The Company's goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
Contact Phio Pharmaceuticals Corp .ir@phiopharma.com
Investor Contact Ashley R. Robinson arr@lifesciadvisors.com
https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-upcoming-presentation-of-ph-894-data-at-asgct-25th-annual-meeting-2022-301537295.html
SOURCE Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp
PHIO Rankings
N/A Ranked by Stock Gains
PHIO Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Marlborough
About PHIO
phio pharmaceuticals corp., a biotechnology company, develops immuno-oncology therapeutics in the united states. it offers intasyl therapeutic platform focuses on silencing tumor-induced suppression of the immune system. the company develops ph-762 which targets the checkpoint protein pd-1 on immune cells for used in adoptive cell transfer (act); ph-804 that targets the suppressive immune receptor tigit, which is a checkpoint protein present on t cells and natural killer cells for used in act; and ph-790 which targets pd-l1 protein that keeps immune cells from attacking nonharmful cells in the body. it has collaborations with the gustave roussy and medigene ag, as well as with helmholtz zentrum mã¼nchen. the company was formerly known as rxi pharmaceuticals corporation and changed its name to phio pharmaceuticals corp. in november 2018. phio pharmaceuticals corp. was incorporated in 2011 and is headquartered in marlborough, massachusetts.
